IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 4166 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  Next article
  Previous article 
  Table of Contents
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (81 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References

 Article Access Statistics
    Viewed3000    
    Printed145    
    Emailed4    
    PDF Downloaded333    
    Comments [Add]    

Recommend this journal

 


 
CORRESPONDENCE
Year : 2006  |  Volume : 38  |  Issue : 5  |  Page : 375
 

Ultra orphan drugs and diseases


Department of Pharmacology and Therapeutics, Govt. Medical College Jammu. (J & K) - 180 001, India

Correspondence Address:
D Kumar
Department of Pharmacology and Therapeutics, Govt. Medical College Jammu. (J & K) - 180 001
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.27716

Rights and Permissions



How to cite this article:
Kumar D, Gupta S. Ultra orphan drugs and diseases. Indian J Pharmacol 2006;38:375

How to cite this URL:
Kumar D, Gupta S. Ultra orphan drugs and diseases. Indian J Pharmacol [serial online] 2006 [cited 2020 Feb 27];38:375. Available from: http://www.ijp-online.com/text.asp?2006/38/5/375/27716


The educational forum, 'Orphan diseases and drugs', (Indian J Pharmacol 2006; 38:171-6) is a very informative article. The various aspects of orphan diseases and drugs have been well covered. A new and interesting term, 'ultra orphan drugs and diseases', was however not included in the article. Ultra orphan drugs[1] is the term designated to drugs which are used to treat exceptionally rare and chronically debilitating or life threatening diseases. Ultra orphan disease is the term designated to diseases with a prevalence of less than 0.18 case per 10,000 population.[2] A few examples of ultra orphan drugs/diseases are[3]

  1. Imantinib for gastrointestinal stromal tumours.
  2. Laronidase for mucopolysaccharidosis type 1.
  3. L-carnitine for genetic carnitine deficiency.
  4. Anagrelide for essential thrombocytopenia.
  5. Miglustat for Gaucher's disease.
  6. Imiglucerase for Gaucher's disease.
  7. Agalsidase for Fabry's disease.
  8. Orfadin for hereditary tyrosinaemia type 1.
  9. Sacrosidase for congenital sucrase isomaltase deficiency.


 
  References Top

1.Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM 2005;98:829-36.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Rawlins M. Managing rare diseases. London: Royal College of Physicians; 2004.   Back to cited text no. 2    
3.McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ 2005;331:1016-9.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]




 

Top
Print this article  Email this article

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow